SESN2 and breast cancer: At the molecular level, the treatment of MDA-MB-453 breast cancer cell line, OVCAR3 ovarian cancer cell line and HeLa cervical adenocarcinoma cell line with nelfinavir and the proteasome inhibitor bortezomib resulted in the upregulation of SESN2 protein.